Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Head & Neck cancer

LBA39 - 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck


19 Sep 2020


Proffered Paper - Head & Neck cancer


Cytotoxic Therapy

Tumour Site

Head and Neck Cancers


Jean Bourhis


Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


J. Bourhis1, X. Sun2, C. Le Tourneau3, Y. Pointreau4, C. Sire5, M. Kaminsky-Forrett6, A. Coutte7, M. Alfonsi8, P. Boisselier9, L. Martin10, J. Delord11, F. Clatot12, J. Biau13, F. Rolland14, K. Gollmer15, S.A. Szyldergemajn16, C. Even17, Y. Tao18

Author affiliations

  • 1 Radiation Oncology, CHUV - Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
  • 2 Radiation Oncology, Hôpital Nord Franche-Comté - HNFC, 90015 - Belfort/FR
  • 3 Department Of Drug Development And Innovation (d3i), Institut Curie, 75248 - Paris/FR
  • 4 Oncology, Centre Jean Bernard, 72000 - Le Mans/FR
  • 5 Oncology, CHU Bretagne Sud, 56322 - Lorient/FR
  • 6 Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 7 Oncology Radiotherapy Department, CHU Amiens-Picardie - Site Sud, 80054 - Amiens/FR
  • 8 Oncology Radiotherapy Department, Institut Ste Catherine, 84082 - Avignon/FR
  • 9 Oncology Radiotherapy Department, ICM Regional Cancer Institute of Montpellier, 34090 - Montpellier/FR
  • 10 Radiation Oncology, Clinique des Ormeaux, 76600 - Le Havre/FR
  • 11 Medical Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 12 Medical Oncology, Centre Henri Becquerel, 76038 - Rouen/FR
  • 13 Radiation Oncology, Centre de Lutte contre le Cancer J. Perrin, 63000 - Clermont Ferrand/FR
  • 14 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 15 Research And Development, Debiopharm International S.A., 1002 - Lausanne/CH
  • 16 Corporate Research And Development Department, Debiopharm International S.A., 1002 - Lausanne/CH
  • 17 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 18 Radiation Oncology, Institut Gustave Roussy, 94805 - Villejuif/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract LBA39


This was a double-blind, randomized phase 2 study of 96 patients with poor prognosis locally advanced, squamous cell carcinoma of the head and neck (LA-SCCHN). Previously reported data showed significant improvements of xevinapant (Debio 1143) versus placebo in addition to chemoradiation (CRT) for the primary endpoint of locoregional control (LRC) rate at 18 months, and demonstrated that addition of Debio 1143 was feasible, safe and did not compromise backbone therapy. Here we report up-dated data on PFS and overall survival (OS).


Patients, stratified by node involvement, tumor localization and HPV-16 status, were randomized (1:1) to receive Debio 1143 or matching placebo at 200 mg/day, oral once daily D1–14 q3w (3 cycles) when added to standard high-dose cisplatin CRT. PFS and OS were analyzed using a Cox model in the intention-to-treat population. Median and survival rates at 36 months were estimated by the Kaplan-Meier method.


As of 21 Jul 2020, the median follow-up was 33 months. Debio 1143 combined with CRT showed a statistically significant improvement in OS vs placebo by reducing the risk of mortality by 51% (HR=0.49, [95%CI: 0.26-0.92], P=0.0261). The 3 years OS rate was 66% (95% CI: 49–78) in the Debio 1143 arm versus 51% (95% CI: 34–65) in the placebo arm; the median OS is not reached with Debio 1143 vs. 36.1 months with placebo (95%CI: 21.8-46.7). Statistically significant improvement in PFS was demonstrated, reducing the risk of disease progression or death by 66% (HR=0.34 [95%CI, 0.17-0.68], p=0.0023) and improving probability of PFS at 36 months to 72% in the Debio 1143 arm compared to 36% in the placebo arm. The predictable and manageable safety profile observed with Debio 1143 + CRT after 2 years remained unchanged after 3 years.


These results with extended follow-up confirm those previously reported, showing now in addition a statistically and clinically significant OS benefit by adding Debio 1143 to standard CRT. The confirmatory phase III Trilynx study (EudraCT Number: 2020-000377-25) is ongoing.

Clinical trial identification

EudraCT: 2013-000044-25; NCT02022098.

Editorial acknowledgement

Legal entity responsible for the study





J. Bourhis: Advisory/Consultancy: BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: Merck; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Debiopharm. C. Le Tourneau: Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Merck Serono; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self): Rakuten; Honoraria (self), Advisory/Consultancy: Nanobiotix; Honoraria (self), Advisory/Consultancy: GSK; Honoraria (self), Advisory/Consultancy: Roche. Y. Pointreau: Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self), Advisory/Consultancy: BMS. M-C. Kaminsky-Forrett: Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self), Advisory/Consultancy: Novartis; Advisory/Consultancy: EMD Serono. P. Boisselier: Honoraria (institution), Advisory/Consultancy: Merck; Advisory/Consultancy: BMS; Advisory/Consultancy: Roche. J-P. Delord: Advisory/Consultancy: BMS; Advisory/Consultancy: Roche; Advisory/Consultancy: MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy: Merck. F. Clatot: Advisory/Consultancy: Merck; Advisory/Consultancy: BMS; Advisory/Consultancy: Lilly. F. Rolland: Advisory/Consultancy: BMS; Advisory/Consultancy: Novartis; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Merck. K. Gollmer: Full/Part-time employment: Debiopharm. S.A. Szyldergemajn: Full/Part-time employment: Debiopharm. C. Even: Advisory/Consultancy: BMS; Advisory/Consultancy: Merck; Advisory/Consultancy: MSD; Advisory/Consultancy: Innate Pharma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.